Evidence map›Paper›PMID 38001039›Full record

ArticleThe Journal of infectious diseases2024

Use of Transcriptional Signatures to Differentiate Pathogen-Specific and Treatment-Specific Host Responses in Patients With Bacterial Bloodstream Infections.

Joshua T Thaden, Richard Ahn, Felicia Ruffin, David W Gjertson, Alexander Hoffmann, Vance G Fowler, Michael R Yeaman

Open access · greenAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Joshua T ThadenDivision of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0002-3250-0697
Richard AhnDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, California, USA.
Felicia RuffinDivision of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA.
David W GjertsonDepartment of Biostatistics, University of California, Los Angeles, Los Angeles, California, USA.
Alexander HoffmannDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, California, USA.
Vance G FowlerDivision of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0002-8048-0897
Michael R YeamanDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Duke University · USQB3 · USUniversity of California, Los Angeles · US

Funding

Systems Epigenomics of Persistent Bloodstream InfectionU19AI172713 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI Monica Cappelletti · 2023 to 2026
$11.6M
Systems Immunolobiology of Antibiotic-Persistent MRSA InfectionU01AI124319 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI YEAMAN, MICHAEL R · 2016 to 2020
$10.1M
HLA Fine Mapping to Elucidate S. aureus SusceptibilityR01AI165671 · NIAID · DUKE UNIVERSITY · PI FOWLER, VANCE G., SCOTT, WILLIAM K · 2021 to 2025
$3.8M
Characterization of a Novel E. coli Type III Secretion System Associated with Increased Patient MortalityK08AI171183 · NIAID · DUKE UNIVERSITY · PI Joshua T Thaden · 2022 to 2026
$895k
NIAID NIH HHS K08 AI171183NIAID NIH HHS R01 AI165671NIAID NIH HHS U01 AI124319NIAID NIH HHS U19 AI172713NIH HHS NIAID U01-AI124319
6 · The paper itself

Abstract

backgroundClinical outcomes in bacterial bloodstream infections (BSIs) are influenced by bacterial species, host immunity, and antibiotic therapy. The mechanisms by which such factors influence outcomes are poorly understood. We aimed to identify bacterial- and antibiotic-specific host transcriptional signatures in patients with bacterial BSI.

methodsRNA sequencing was performed on blood samples from patients with BSI due to gram-negative (GN) versus gram-positive (GP) pathogens: Escherichia coli (n = 30) or Klebsiella pneumoniae (n = 28) versus methicillin-susceptible Staphylococcus aureus (MSSA) (n = 24) or methicillin-resistant S. aureus (MRSA) (n = 58). Patients were matched by age, sex, and race.

resultsNo significant host transcriptome differences were detected in patients with E. coli versus K. pneumoniae BSI, so these were considered together as GN BSI. Relative to S. aureus BSI, patients with GN BSI had increased activation of the classic complement system. However, the most significant signal was a reduction in host transcriptional signatures involving mitochondrial energy transduction and oxidative burst in MRSA versus MSSA. This attenuated host transcriptional signature remained after controlling for antibiotic therapy.

conclusionsGiven the importance of immune cellular energetics and reactive oxygen species in eliminating hematogenous or intracellular MRSA, these findings may offer insights into its persistence relative to other bacterial BSIs.

Indexed as

Anti-Bacterial AgentsBacteremiaAdultAgedEscherichia coliFemaleGene Expression ProfilingHost-Pathogen InteractionsHumansKlebsiella pneumoniaeMaleMethicillin-Resistant Staphylococcus aureusMiddle AgedSequence Analysis, RNAStaphylococcus aureusTranscriptomeAnti-Bacterial AgentsbacteremiaEscherichia coliKlebsiella pneumoniaeStaphylococcus aureustranscriptome

Identifiers

PMID38001039
PMCPMC11095544
OpenAlexW4388989890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.